Positron emission tomography Repeatability Evaluation of Tissue Zirconium 89ZR CrEfmirLimab berdoxam uptake (PRETZCEL)

ImaginAb (United States)0 个研究点目标入组 12 人开始时间: 2022年10月3日最近更新: 2024年7月8日

适应症

试验速览

暂无简介。

•All participants:
•1. Aged =18 years
•2. =1 imageable primary or metastatic lesion =1 cm in the lymph nodes or soft tissue excluding bone on the most recent standard of care imaging done within the last 3 months
•3. Agree to follow contraceptive advice while on study until 33 days after ending participation
•1. Melanoma on single or multiple agent Immune Checkpoint Blockade (ICB) therapy with stable response status following initiation of therapy
•2. Stable disease observed over =2 consecutive standard of care CT scans (usually done 8-12 weeks apart) after initiation of therapy
•1. Untreated renal cell carcinoma on active surveillance

•1. Uncontrolled infection or other concurrent malignancies or conditions that may confound interpretation of the scans in the opinion of the study doctor
•2. Urinary catheters or stoma bags
•3. Patients who have received a COVID vaccine can be included in the study but can only be scanned after a washout period of 2 weeks after the vaccine. If patients have a COVID vaccine after the first PET-CT scan, the second PET-CT scan will be delayed for =2 weeks after the COVID vaccine.
•4. Taking steroids, except those on replacement dose of steroids for adrenal or pituitary insufficiency. Patients requiring steroids as therapy for an unresolved immune therapy related adverse event will be excluded.
•5. Taking immunosuppressive medication e.g. cyclosporine, azathioprine, or janus kinase inhibitors
•6. Enrolled in another therapeutic intervention study
•7. Any other contraindication that makes the patient unsuitable to take part in the study in the opinion of the investigator
•8. Women of child bearing potential who are pregnant or breastfeeding on study entry
•9. Unable to provide informed consent

发起方

ImaginAb (United States)